Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) have been assigned a consensus rating of “Hold” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $24.40.
Several equities analysts have recently weighed in on SLP shares. TD Cowen lowered their price target on Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a report on Friday, April 10th. Zacks Research cut Simulations Plus from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Wall Street Zen raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Weiss Ratings cut Simulations Plus from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, May 21st.
Check Out Our Latest Research Report on SLP
Hedge Funds Weigh In On Simulations Plus
Simulations Plus Trading Up 7.5%
Shares of SLP opened at $16.71 on Friday. The business’s fifty day simple moving average is $13.74 and its two-hundred day simple moving average is $15.61. Simulations Plus has a 12 month low of $11.09 and a 12 month high of $32.51. The company has a market cap of $337.54 million, a price-to-earnings ratio of -5.34 and a beta of 1.28.
Simulations Plus (NASDAQ:SLP – Get Free Report) last issued its earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.27 by $0.08. The business had revenue of $24.29 million for the quarter, compared to the consensus estimate of $21.66 million. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%. As a group, research analysts forecast that Simulations Plus will post 0.85 EPS for the current year.
Simulations Plus Company Profile
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
See Also
- Five stocks we like better than Simulations Plus
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
